DexCom, Inc. Forecasted to Post Q1 2018 Earnings of ($0.32) Per Share (DXCM)

DexCom, Inc. (NASDAQ:DXCM) – Oppenheimer issued their Q1 2018 earnings per share estimates for shares of DexCom in a report released on Monday. Oppenheimer analyst S. Lichtman anticipates that the medical device company will earn ($0.32) per share for the quarter. Oppenheimer currently has a “Buy” rating and a $67.00 target price on the stock. Oppenheimer also issued estimates for DexCom’s Q3 2018 earnings at ($0.04) EPS, Q4 2018 earnings at $0.12 EPS and FY2019 earnings at ($0.06) EPS.

Other equities analysts also recently issued research reports about the stock. Northland Securities reaffirmed a “sell” rating and set a $40.00 target price on shares of DexCom in a research note on Tuesday, January 16th. ValuEngine downgraded shares of DexCom from a “hold” rating to a “sell” rating in a research note on Thursday, February 8th. Zacks Investment Research downgraded shares of DexCom from a “hold” rating to a “sell” rating in a research note on Tuesday. BidaskClub downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 22nd. Finally, Barclays decreased their target price on shares of DexCom from $60.00 to $57.00 and set an “equal weight” rating for the company in a research note on Thursday, November 2nd. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $67.44.

DexCom (NASDAQ DXCM) opened at $55.74 on Tuesday. DexCom has a one year low of $42.62 and a one year high of $86.32. The firm has a market cap of $4,750.99, a P/E ratio of -97.79 and a beta of 0.21. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84.

A number of hedge funds have recently modified their holdings of DXCM. American International Group Inc. purchased a new stake in DexCom in the fourth quarter worth approximately $116,000. Advisor Group Inc. boosted its holdings in DexCom by 104.9% in the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after purchasing an additional 837 shares during the last quarter. Thompson Davis & CO. Inc. purchased a new stake in DexCom in the fourth quarter worth approximately $137,000. Zions Bancorporation boosted its holdings in DexCom by 36,222.2% in the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after purchasing an additional 3,260 shares during the last quarter. Finally, Toronto Dominion Bank boosted its holdings in DexCom by 251.0% in the third quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after purchasing an additional 2,608 shares during the last quarter.

In related news, EVP Andrew K. Balo sold 6,490 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $60.00, for a total value of $389,400.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Richard Doubleday sold 1,635 shares of the firm’s stock in a transaction that occurred on Friday, November 24th. The stock was sold at an average price of $55.53, for a total transaction of $90,791.55. Following the completion of the sale, the executive vice president now owns 65,049 shares in the company, valued at approximately $3,612,170.97. The disclosure for this sale can be found here. Insiders have sold 48,140 shares of company stock valued at $2,743,281 in the last three months. 1.70% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This article was first published by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://weekherald.com/2018/02/15/dexcom-inc-forecasted-to-post-q1-2018-earnings-of-0-32-per-share-dxcm.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply